Study Results from COTA, PreciseDx, and Baptist Health South Florida Confirm Novel AI Test, PreciseBreast is Equivalent to Oncotype DX at Predicting Breast Cancer Recurrence
Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ -- COTA Inc., a...